Rapid Information on OLM No.170 130102.doc

Rapid Information on Olmesartan and other ARBs No.170 2013/01/02 　　　　　　　　　　　　　　　　　 　　　　　　　　Be the first to know! 　　　 　　 (Toru Komai, Ph.D.) 170-1: The OMEGA study showed that the severity of hypertension (achieved blood pressure) is associated with the incidence of CVD, and suggested that tight blood pressure control and salt restriction are important for preventing stroke. Title：Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study. 2 170-2: The chronotherapy of conventional hypertension medications constitutes a new strategy for enhancing the control of daytime and nighttime SBP and DBP levels, normalizing the dipping status of their 24-h patterning. (A review) Title：Administration-Time Differences in Effects of Hypertension Medications on Ambulatory Blood Pressure Regulation. 3-4 170-3: Olmesartan was found to be effective in delaying or preventing the development of microalbuminuria in diabetic individuals at high cardiovascular risk. (Expert review on the ROADMAP study) Title：Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes. 5 170-4: The angioedema risk was lower with ARBs than with ACE inhibitors or aliskiren among patients who received these drugs in real-world clinical settings. Among individual ARBs, the risk of olmesartan was less than others. Title：Comparative risk for angioedema associated with the use of drugs that target the Renin-Angiotensin-aldosterone system. 6 170-1: The OMEGA study showed that the severity of hypertension (achieved blood pressure) is associated with the incidence of CVD, and suggested that tight blood pressure control and salt restriction are important for preventing stroke.